Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL452095 | 1.00 | MAPT (0.41) | MAPTCYP2C19CYP1A2CYP3A4RAB9A | |
| SCHEMBL27790510 | 0.81 | GAA (0.39) | MAPTSMN1; SMN2ABCG2LMNAKMT2A | |
| SCHEMBL455531 | 0.80 | NPC1 (0.40) | MAPTRAB9ASMN1; SMN2ABCG2KMT2A | |
| SCHEMBL844135 | 0.75 | MGAM (0.50) | CYP2C19CYP1A2RAB9AKDM4EHPGD | |
| SCHEMBL10650277 | 0.74 | SMN1; SMN2 (0.38) | MAPTCYP2C19CYP1A2CYP3A4RAB9A | |
| SCHEMBL4508078 | 0.73 | PSMD14 (0.45) | SMN1; SMN2KDM4E | |
| SCHEMBL1680488 | 0.73 | NPC1 (0.51) | MAPTRAB9ASMN1; SMN2NPSR1POLB | |
| SCHEMBL27790506 | 0.73 | ADORA2A (0.38) | MAPTRAB9ASMN1; SMN2POLBABCG2 | |
| Hydrochloric Acid SCHEMBL27679163 | 0.72 | PSMD14 (0.44) | SMN1; SMN2KDM4E | |
| SCHEMBL11069346 | 0.70 | MGAM (0.57) | MAPTCYP2C19CYP1A2CYP3A4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065219-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-03-15 | — | — | US | disclosed |
| US-8076350-B2 | 3H-(4's)-1'-azaspiro[benzofuran-2,4']-tricyclo[3.3.1.13,7]decane; for therapy of memory disorder, cognitive disorder, neurodegeneration, and neurodevelopmental disorder; attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment | ABBOTT LABORATORIES (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2114943-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | Abbott Laboratories (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008079570-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065219-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | MAPT 4366/4885CYP2C19 212/4885CYP1A2 92/4885 |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | MAPT 4383/4885CYP2C19 202/4885CYP1A2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.